KR20150107738A - 암의 면역 프로그래밍 및 치료를 위한 선택적 글라이코시다제 섭생 - Google Patents

암의 면역 프로그래밍 및 치료를 위한 선택적 글라이코시다제 섭생 Download PDF

Info

Publication number
KR20150107738A
KR20150107738A KR1020157018524A KR20157018524A KR20150107738A KR 20150107738 A KR20150107738 A KR 20150107738A KR 1020157018524 A KR1020157018524 A KR 1020157018524A KR 20157018524 A KR20157018524 A KR 20157018524A KR 20150107738 A KR20150107738 A KR 20150107738A
Authority
KR
South Korea
Prior art keywords
cancer
glycosidase
patient
regimen
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157018524A
Other languages
English (en)
Korean (ko)
Inventor
엘리스 클라인
Original Assignee
엘리스 클라인
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엘리스 클라인 filed Critical 엘리스 클라인
Publication of KR20150107738A publication Critical patent/KR20150107738A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01049—Alpha-N-acetylgalactosaminidase (3.2.1.49)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01051—Alpha-L-fucosidase (3.2.1.51)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
KR1020157018524A 2013-01-18 2014-01-17 암의 면역 프로그래밍 및 치료를 위한 선택적 글라이코시다제 섭생 Ceased KR20150107738A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361754056P 2013-01-18 2013-01-18
US61/754,056 2013-01-18
PCT/US2014/011995 WO2014113641A1 (en) 2013-01-18 2014-01-17 Selective glycosidase regimen for immune programming and treatment of cancer

Publications (1)

Publication Number Publication Date
KR20150107738A true KR20150107738A (ko) 2015-09-23

Family

ID=51210082

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157018524A Ceased KR20150107738A (ko) 2013-01-18 2014-01-17 암의 면역 프로그래밍 및 치료를 위한 선택적 글라이코시다제 섭생

Country Status (9)

Country Link
US (2) US20150352193A1 (cg-RX-API-DMAC10.html)
EP (2) EP2945644A4 (cg-RX-API-DMAC10.html)
JP (1) JP2016505043A (cg-RX-API-DMAC10.html)
KR (1) KR20150107738A (cg-RX-API-DMAC10.html)
CN (1) CN104936611A (cg-RX-API-DMAC10.html)
AU (2) AU2014207429B2 (cg-RX-API-DMAC10.html)
CA (1) CA2896899A1 (cg-RX-API-DMAC10.html)
MX (1) MX2015009260A (cg-RX-API-DMAC10.html)
WO (1) WO2014113641A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6673696B2 (ja) 2012-09-28 2020-03-25 クライン，エリス 感染症治療用グリコシダーゼレジメン
WO2016162867A1 (en) * 2015-04-08 2016-10-13 Efranat Ltd. Combination therapy of macrophage activating factor and pd-1 signaling inhibitors
CN105256036B (zh) * 2015-10-26 2019-02-12 中国人民解放军第二军医大学 一种检测血清中lncARSR的试剂盒及其在检测肾癌舒尼替尼耐药中的应用
JP7462560B2 (ja) 2018-01-03 2024-04-05 パレオン ファーマシューティカルズ インコーポレイテッド 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびそれらの使用方法
CN111500715B (zh) * 2019-01-31 2022-03-11 北京大学 用于预测结直肠癌术后复发与转移的检测组合物、检测装置、检测试剂盒及应用
US11554145B2 (en) * 2019-01-31 2023-01-17 The Chinese University Of Hong Kong Therapeutic and prophylactic treatment for colorectal cancer
MX2022000032A (es) * 2019-07-03 2022-06-15 Palleon Pharmaceuticals Inc Sialidasas recombinantes y métodos de utilización de las mismas.

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4071408A (en) 1976-11-01 1978-01-31 Research Corporation Neuraminidase
DE3302160A1 (de) 1983-01-22 1984-07-26 Ing. Erich Pfeiffer GmbH & Co KG, 7760 Radolfzell Betaetigbare dosiereinrichtung
DE3315334A1 (de) 1983-04-28 1984-10-31 Pfeiffer Erich Gmbh & Co Kg Zerstaeuber- oder dosierpumpe
DE3715301A1 (de) 1987-05-08 1988-11-24 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung fuer medien
DE3722470A1 (de) 1987-07-08 1989-01-19 Pfeiffer Erich Gmbh & Co Kg Handbetaetigbare austragvorrichtung fuer medien
US5326749A (en) 1989-11-20 1994-07-05 Nobuto Yamamoto Macrophage activating factor from vitamin D binding protein
IT1252228B (it) 1991-12-17 1995-06-05 T Associated Bio Technologies Procedimento per la produzione di neuraminidasi
US6562588B2 (en) 1993-05-17 2003-05-13 Genentech, Inc. Sialidase and recombinant cell lines
US5985859A (en) 1994-04-14 1999-11-16 The University Of Alabama Methods of inhibiting bacterial sialidase
US6410269B1 (en) * 1995-06-07 2002-06-25 Nobuto Yamamoto Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis
DE19525734A1 (de) 1995-07-14 1997-01-16 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für fließfähige Medien, insbesondere für den Austrag in nur einem Hub
EP1272211B1 (en) * 2000-04-07 2007-06-06 Signal Coordinating Therapy, Inc. Methods and compositions for treating neoplasms
DE10146815B4 (de) 2001-09-18 2005-05-04 Ing. Erich Pfeiffer Gmbh Spender für Medien
US7201296B2 (en) 2001-09-21 2007-04-10 Ing. Erich Pfeiffer Gmbh Dosing device with a pumping device
DE10164452A1 (de) 2001-12-21 2003-07-03 Pfeiffer Erich Gmbh & Co Kg Spender für Medien
US7081340B2 (en) 2002-03-13 2006-07-25 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
CA3061769C (en) 2003-06-24 2021-10-26 Genomic Health, Inc. Methods of predicting the likelihood of long-term survival of a human patient with node-negative, estrogen receptor (er) positive, invasive ductal breast cancer without the recurrence of breast cancer
ES2905579T3 (es) 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
US7892752B2 (en) * 2005-04-26 2011-02-22 Dwek Raymond A Glycosylation markers for cancer diagnosing and monitoring
US20110038856A1 (en) * 2006-11-02 2011-02-17 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
CA2676686C (en) 2007-02-20 2015-12-15 Dsm Ip Assets B.V. Novel sialidase
CA2692417C (en) * 2007-07-03 2017-03-21 Children's Hospital & Research Center At Oakland Polysialic acid derivatives, methods of production, and uses in enhancing cancer antigen production and targeting
AU2009246009A1 (en) 2008-05-14 2009-11-19 University Health Network Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
US20110238322A1 (en) 2008-11-03 2011-09-29 Precision Therapeutics, Inc. Methods of simulating chemotherapy for a patient
US20100331210A1 (en) 2009-05-29 2010-12-30 Precision Therapeutics, Inc. Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
CA2771900A1 (en) * 2009-08-22 2011-03-10 Charles Knezevich Tumoricidal, bactericidal, or viricidal macrophage activation
HRP20161147T1 (hr) * 2011-09-14 2016-11-18 Saisei Mirai Clinic Farmaceutski sastav i postupak njegove proizvodnje

Also Published As

Publication number Publication date
EP2945644A1 (en) 2015-11-25
CA2896899A1 (en) 2014-07-24
EP2945644A4 (en) 2016-10-26
MX2015009260A (es) 2015-10-15
JP2016505043A (ja) 2016-02-18
EP3563864A1 (en) 2019-11-06
WO2014113641A1 (en) 2014-07-24
US20150352193A1 (en) 2015-12-10
CN104936611A (zh) 2015-09-23
AU2014207429A1 (en) 2015-07-02
US20190201503A1 (en) 2019-07-04
AU2019200688B2 (en) 2020-08-06
AU2014207429B2 (en) 2018-11-01
AU2019200688A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
AU2019200688B2 (en) Selective glycosidase regimen for immune programming and treatment of cancer
Hester et al. Immunotherapy in pancreatic adenocarcinoma: beyond “copy/paste”
JP7175334B2 (ja) 免疫刺激剤による癌治療
US12485174B2 (en) HDAC6-activated macrophages, compositions, and uses thereof
Hargadon Strategies to improve the efficacy of dendritic cell-based immunotherapy for melanoma
Wiltrout et al. IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside
US20170340658A1 (en) Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
EP2684569A1 (en) A composition for treatment of advanced prostate cancer
EP2364163B1 (en) Composition comprising in vitro expanded t-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer
JP6382934B2 (ja) 癌治療のためのａｄｉ−ｐｅｇ２０抗体に対して低減された交差反応性を有するアルギニンデイミナーゼ
TW201340979A (zh) 利用精胺酸去亞胺酶之治療方法
JP2020503252A (ja) Ｔ細胞応答を促進するための方法
JP2021519302A5 (cg-RX-API-DMAC10.html)
Perera et al. STimulator of INterferon genes agonism accelerates antitumor activity in poorly immunogenic tumors
JP2016505043A5 (cg-RX-API-DMAC10.html)
Zhang et al. The application of cytidyl guanosyl oligodeoxynucleotide can affect the antitumor immune response induced by a combined protocol of cryoablation and dendritic cells in Lewis lung cancer model
Verner et al. Emerging roles of type 1 innate lymphoid cells in tumour pathogenesis and cancer immunotherapy
WO2015157299A2 (en) Inhibition of lactate dehydrogenase 5 (ldh-5) binding, incorporation, internalization and/or endocytosis to immune cells
Lin et al. Are friends or foes? New strategy for head and neck squamous cell carcinoma treatment via immune regulation
Sukhatme et al. Repurposing Food and Drug Administration–Approved Drugs to Promote Antitumor Immunity
WO2023247660A1 (en) Combination therapies
Schwaab et al. Tumor‐related immunity in prostate cancer patients treated with human recombinant granulocyte monocyte‐colony stimulating factor (GM‐CSF)
Vertesi Immune response developing in tumorous organism as a result of immunotherapy. Chance of recovery?
JP2022534412A (ja) プロカスパーゼ‐３の活性化及びがんの治療のための免疫療法
US20250325589A1 (en) Glycopeptide mediated t cell immunity and anti-tumor efficacy in cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150710

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190116

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200624

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20201103

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200624

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20201103

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200821

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190116

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20210218

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210202

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20201103

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200821

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20200624

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190116

X601 Decision of rejection after re-examination